Form 4: Adaptive Bio Officer Sells Shares Under 10b5-1 Plan

Adaptive Biotechnologies' Chief People Officer, Francis Lo, exercised stock options and sold common stock totaling 79,590 shares on January 12, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Francis Lo, Chief People Officer of Adaptive Biotechnologies Corp (ADPT), engaged in stock transactions on January 12, 2026.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 15, 2025.
• Lo exercised options to acquire a total of 79,590 shares of common stock at various prices: 36,650 shares at $7.8, 7,723 shares at $12.14, 21,002 shares at $8.46, and 14,215 shares at $3.99.
• Concurrently, Lo sold 79,590 shares of common stock at a price of $17.73 per share.
• Following these transactions, Lo directly beneficially owns 315,978 shares of common stock.
• Lo also indirectly owns 2,500 shares of common stock through a spouse.
• Remaining stock options include 75,500 at $7.8 (fully vested), 177,615 at $12.14 (partially vested), 87,074 at $8.46 (partially vested), and 90,641 at $3.99 (partially vested).

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions under a pre-planned 10b5-1 trading plan, which is a standard practice for executive compensation and personal financial management. It does not indicate positive or negative company performance.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned activity and reducing concerns about opportunistic insider trading.
• The sale price of $17.73 is significantly higher than the exercise prices of the options, indicating a profitable transaction for the officer.

Negatives

• An officer selling a substantial number of shares, even under a 10b5-1 plan, could be perceived negatively by some investors, though it is often for personal financial planning.

Future Outlook

The filing does not provide forward-looking statements or guidance regarding the company's performance or strategy, focusing solely on insider transactions.

Industry Context

This Form 4 filing is a routine disclosure of an insider's equity transactions and does not provide information to analyze broader industry trends or competitive positioning for Adaptive Biotechnologies.

Stakeholder Impact

• Shareholders: May note the officer's sale, but the 10b5-1 plan mitigates concerns of opportunistic selling. The officer retains significant direct and indirect holdings, as well as substantial unexercised options.
• Employees: No direct impact mentioned.

Next Steps

• Continued vesting of remaining stock options according to their respective schedules.

Key Dates

Keywords

Adaptive Biotechnologies, ADPT, Form 4, Insider Trading, Stock Options, Common Stock, Rule 10b5-1, Chief People Officer, Francis Lo, Equity Sales